That is the title of a paper published today in Future Oncology with co-authors Erin Mulvey, Kyi-Sin Than, Sanjana Muthukrishnan, Alex Mutebi, Anindit Chhibber, Anthony Wang, Abualbishr Alshreef, Diala Harb, Victor Gonzalez, Sarah Quinlan, Vardhaman Patel and Patrick Connor Johnson. The study was conducted in collaboration with the Lymphoma Research Foundation. The abstract is below:
Background: Two recently approved bispecific antibodies (bsAbs) for relapsed/refractory diffuse largeB-cell lymphoma (DLBCL) include epcoritamab (subcutaneous, SC) administered until progression (TTP),and glofitamab (intravenous, IV) for fixed duration (FTD). Understanding patient preferences for treat-ment attributes is critical for patient-centered decision-making.
Methods: A discrete-choice experiment among 123 DLBCL patients assessed preferences for bsAbs across six attributes: median overall survival (OS, 12- vs 18-months), 24-month complete response (CR)(55% vs 62%), grade 3–4 cytokine release syndrome risk (CRS, 2% vs 5%), CRS-related hospitalization(2% vs 56%), duration (FTD vs TTP) and administration (SC vs IV). Preference weights were estimated using conditional logistic regression.
Results: CRS and CRS-related hospitalization were the strongest drivers of preferences (1.83, P < 0.001),followed by OS (1.14, P < 0.001), CR (1.13, P < 0.001), duration (0.48, P < 0.001), and administration (0.02,P = 0.877). Patients favored FTD, but preferred TTP if it reduced CRS (79.3%) or improved survival(65.8%). Patients indicated the importance of efficacy attributes (OS, 86.2%; CR, 85.4%) and quality oflife (QoL, 71.5%) in decision-making.
Conclusion: Efficacy and safety were the most important factors, along with QoL. Patients favored FTD but were willing to tradeoff for TTP with increased efficacy or safety. These findings may guide physician/patient discussions in therapy selection.
You can read the full paper here.
